289 related articles for article (PubMed ID: 33229411)
1. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
Bhatt RS; Berjis A; Konge JC; Mahoney KM; Klee AN; Freeman SS; Chen CH; Jegede OA; Catalano PJ; Pignon JC; Sticco-Ivins M; Zhu B; Hua P; Soden J; Zhu J; McDermott DF; Arulanandam AR; Signoretti S; Freeman GJ
Cancer Immunol Res; 2021 Feb; 9(2):156-169. PubMed ID: 33229411
[TBL] [Abstract][Full Text] [Related]
2. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.
Wei Y; Ren X; Galbo PM; Moerdler S; Wang H; Sica RA; Etemad-Gilbertson B; Shi L; Zhu L; Tang X; Lin Q; Peng M; Guan F; Zheng D; Chinai JM; Zang X
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34244312
[TBL] [Abstract][Full Text] [Related]
3. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
4. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
[TBL] [Abstract][Full Text] [Related]
5. Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model.
Ren X; Corrigan DT; Zang X
STAR Protoc; 2022 Dec; 3(4):101818. PubMed ID: 36386885
[TBL] [Abstract][Full Text] [Related]
6. The Importance of HHLA2 in Solid Tumors-A Review of the Literature.
Kula A; Koszewska D; Kot A; Dawidowicz M; Mielcarska S; Waniczek D; Świętochowska E
Cells; 2024 May; 13(10):. PubMed ID: 38786018
[TBL] [Abstract][Full Text] [Related]
7. Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2.
Campbell KS
Cancer Immunol Res; 2021 Feb; 9(2):128. PubMed ID: 33536266
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
[TBL] [Abstract][Full Text] [Related]
9. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.
Zhao R; Chinai JM; Buhl S; Scandiuzzi L; Ray A; Jeon H; Ohaegbulam KC; Ghosh K; Zhao A; Scharff MD; Zang X
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9879-84. PubMed ID: 23716685
[TBL] [Abstract][Full Text] [Related]
10. Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.
Ying H; Xu J; Zhang X; Liang T; Bai X
EBioMedicine; 2022 May; 79():103987. PubMed ID: 35439678
[TBL] [Abstract][Full Text] [Related]
11. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
[TBL] [Abstract][Full Text] [Related]
12. Regulation of HHLA2 expression in kidney cancer and myeloid cells.
Shigemura T; Perrot N; Huang Z; Bhatt RS; Sheshdeh AB; Ahmar NE; Ghandour F; Signoretti S; McDermott DF; Freeman GJ; Mahoney KM
BMC Cancer; 2023 Oct; 23(1):1039. PubMed ID: 37891555
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.
Palmer WH; Leaton LA; Campos Codo A; Crute B; Roest J; Zhu S; Petersen J; Tobin RP; Hume PS; Stone M; van Bokhoven A; Gerich ME; McCarter MD; Zhu Y; Janssen WJ; Vivian JP; Trowsdale J; Getahun A; Rossjohn J; Cambier J; Loh L; Norman PJ
Sci Immunol; 2023 Jun; 8(84):eade5343. PubMed ID: 37390222
[TBL] [Abstract][Full Text] [Related]
14. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.
Janakiram M; Chinai JM; Fineberg S; Fiser A; Montagna C; Medavarapu R; Castano E; Jeon H; Ohaegbulam KC; Zhao R; Zhao A; Almo SC; Sparano JA; Zang X
Clin Cancer Res; 2015 May; 21(10):2359-66. PubMed ID: 25549724
[TBL] [Abstract][Full Text] [Related]
15. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y
Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158
[TBL] [Abstract][Full Text] [Related]
16. B7-H7: A potential target for cancer immunotherapy.
Su Q; Du J; Xiong X; Xie X; Wang L
Int Immunopharmacol; 2023 Aug; 121():110403. PubMed ID: 37290327
[TBL] [Abstract][Full Text] [Related]
17. The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.
Xiao Y; Li H; Yang LL; Mao L; Wu CC; Zhang WF; Sun ZJ
Dis Markers; 2019; 2019():5421985. PubMed ID: 31089395
[TBL] [Abstract][Full Text] [Related]
18. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
19. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
Chandrasekaran D; Sundaram S; N K; R P
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2951-2957. PubMed ID: 31653140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]